A 42-year-old premenopausal woman presents to the oncology clinic for a scheduled evaluati… — USMLE Step 3

A $42$ -year-old premenopausal woman presents to the oncology clinic for a scheduled evaluation prior to her next infusion. She is currently undergoing treatment for early-stage, HER2-amplified, estrogen receptor-negative breast cancer. She successfully completed a course of adjuvant paclitaxel and is currently receiving maintenance intravenous trastuzumab every $3$ weeks.

During the clinical interview, the patient reports feeling well and denies shortness of breath, orthopnea, paroxysmal nocturnal dyspnea, or peripheral swelling. She exercises moderately for $45$ minutes most days of the week without limitation. Vital signs include a blood pressure of $118/74$ mmHg and a heart rate of $72$ /min. Physical examination reveals clear lungs bilaterally, no jugular venous distention, and a regular heart rate with no S3 gallop.

As part of her routine surveillance, serial echocardiography has been performed with the following results:

Timepoint	Left Ventricular Ejection Fraction (LVEF)
Pre-treatment (Baseline)	$66\%$
Week $12$	$62\%$
Week $24$ (Current)	$48\%$

Based on the patient's surveillance data, which of the following is the most appropriate next step in management?

Withhold trastuzumab and repeat echocardiography in $4$ weeksAnswer
B
Discontinue trastuzumab permanently and transition to an alternative targeted agent
C
Continue trastuzumab at the current dose and initiate lisinopril therapy
D
Reduce the trastuzumab dose by $50\%$ and repeat echocardiography at the next scheduled $12$ -week interval
E
Continue trastuzumab and order cardiac magnetic resonance imaging to evaluate for myocardial fibrosis

Answer

The most appropriate next step is to withhold trastuzumab and repeat echocardiography in

4

weeks.

The correct answer identifies the guideline-concordant management for asymptomatic trastuzumab-induced left ventricular dysfunction. Trastuzumab causes Type II cardiotoxicity, which involves loss of myocardial contractility without the irreversible myocyte destruction seen with anthracyclines. Because this toxicity is frequently reversible, standard oncology protocols dictate that for an absolute LVEF decline of

16\%

or greater, or a decline to below

50\%

, the medication must be temporarily held. An echocardiogram should then be repeated in

4

weeks. If the LVEF recovers to acceptable parameters, the medication can safely be resumed in the majority of cases.

Step-by-Step Solution

Identify the patient's current clinical status and medication.

The patient is asymptomatic but is receiving trastuzumab, an agent specifically known to cause Type II (typically reversible) cardiotoxicity.

Establishing the patient's symptom status and specific pharmacology is required to select the correct toxicity monitoring algorithm.

Analyze the longitudinal surveillance data against baseline measurements.

The patient's LVEF has dropped from a baseline of

66\%

to a current value of

48\%

. This is an absolute decrease of

18\%

and falls below the standard institutional lower limit of normal (

50\%

Trastuzumab guidelines dictate management based on exact percentage drops from baseline, not just the absolute current value.

Apply standard oncologic monitoring guidelines for HER2-targeted therapy.

For an asymptomatic patient with an absolute LVEF decrease of

\ge 16\%

from baseline, or a decrease of

10\%-15\%

to a value below institutional limits of normal, trastuzumab must be withheld.

Continuing the medication when these thresholds are crossed significantly increases the risk of progression to symptomatic heart failure.

Determine the mandatory follow-up sequencing.

Echocardiography should be repeated in

4

weeks to assess for reversibility before making any decision regarding permanent discontinuation.

Type II cardiotoxicity often resolves upon holding the drug, allowing for safe resumption of life-saving cancer therapy if LVEF recovers.

Key Concept

Trastuzumab-induced cardiotoxicity presents as asymptomatic, reversible left ventricular systolic dysfunction (Type II cardiotoxicity), necessitating strict serial monitoring and algorithmic withholding of the drug for absolute LVEF declines

\ge 16\%

, followed by reassessment in

4

weeks.

Estimated Time:1m 30s

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic